Philogen stock
PHIL.MIMILPhilogen S.p.A., HealthcareISIN IT0005373789
68Score 68 out of 100, Neutral
Price and trend
52 / 100
Price history
−8.9% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.6% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 17% below its 52-week high. Largest decline in 3 years: 28% (June 2025 to April 2026).
Chart figures for advanced users
- SMA 50$24.38
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.01
- The lowest closing price of the last twelve months.
- Resistance$28.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Philogen S.p.A. belongs to the Biotechnology industry (Italy) and, with a market value of $948.15M, is number 191 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $348.3M (up 324.8% year on year) and earnings of $254.5M (up 407.1%).
- MEQIRI Score 68 out of 100 (Neutral): rank 167 of 702 in Healthcare, median 53.
Show more
- The P/E is 3.8 (Biotechnology median 21.7, own median of recent years 10.7).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 3.8, Biotechnology median 21.7, own median 10.7.Valuation 100
- High return on capitalReturn on invested capital 82.4% in fiscal 2025, Biotechnology median −24.3%.Profitability 96
- High marginNet margin 71.4% over the last 12 months, Biotechnology median −103.7%.Profitability 96
Weaknesses
- DilutionShare count up 38% since 2020.Capital allocation 54
Its standout strengths are valuation and profitability, while momentum holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
Valuation
Valuation signal
UndervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue fell 53.4% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 325% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 86%, operating 80%, net 73%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Mar 2027in 132 days
- Last reported
- 25 Sep 2026EPS reported −$0.54 (expected −$0.45)below expectations
Analyst estimates
- Earnings per share
- $2.30+220.0%
- Revenue
- $164.57M+87.0%
- Earnings per share
- $0.28+200.4%
- Revenue
- $59.5M+67.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Philogen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Jade BiosciencesJBIO $1.01B42
- Corvus PharmaceuticalsCRVS $982.22M37
- ImmaticsIMTX $975.63M28
- Odyssey TherapeuticsODTX $966.16M44
- Monte Rosa TherapeuticsGLUE $947.69M32
- Silence TherapeuticsSLN $935.23M45
- Pharming GroupPHARM.AS $910.96M49
- ORIC PharmaceuticalsORIC $881.05M32
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.